Press Release Details

Adicet Bio to Present at Upcoming Investor Conferences

May 18, 2022 at 4:00 PM EDT

MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--May 18, 2022-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in May and June.

Details of the events are as follows:

H.C. Wainwright Global Investment Conference, May 23-26, 2022

  • An on-demand presentation will be available beginning Tuesday, May 24th, 2022, at 7:00 A.M. ET.

Jefferies Healthcare Conference, June 8-10, 2022

  • Chen Schor, President & CEO, will present on Friday, June 10, 2022 at 8:30 A.M. ET.

The live audio webcast of the presentations can be accessed on the Investors section of Adicet Bio’s website at An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge

Janhavi Mohite
Stern Investor Relations, Inc.

Source: Adicet Bio, Inc.